arrow
J

Juan Pablo Alderuccio

University of Miami Miller School of Medicine
H指数:21
被引数:1,780

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes for Patients With Primary Gastrointestinal Follicular Lymphoma: Results From a Multicenter Analysis

原发性胃肠道滤泡性淋巴瘤患者的预后:多中心分析结果

2026-11-110
OAAI
Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study

免疫缺陷相关性原发性中枢神经系统淋巴瘤:一项国际原发性中枢神经系统淋巴瘤协作组(IPPC)研究

Blood
IF23.1
2026-03-200
OAAI
Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma

大b细胞淋巴瘤继发性中枢神经系统受累的治疗相关结果和复发模式

Blood
IF23.1
2026-01-070
PRE
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies

多中心研究:ALK阳性大B细胞淋巴瘤:ALK抑制剂和生物学指导治疗时代的结局

2025-09-030
PRE
Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study

CAR T细胞疗法中结外受累对复发或难治性大B细胞淋巴瘤患者预后的影响——一项多中心队列研究的结果

2025-06-210
OAAI
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature

边缘区淋巴瘤的转化:一项前瞻性队列研究及文献荟萃分析的结果

2024-11-270
OAAI
CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL)- a Multicenter Retrospective Study

CD20xCD3 双特异性抗体作为复发/难治性(R/R)大型B细胞淋巴瘤(LBCL)的标准治疗方案(SOC)——一项多中心回顾性研究

BLOOD
IF23.1
2024-11-050
PRE
PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

PRIMAVERA:一项模块化I/II期研究,旨在评估AZD3470(一种蛋白质精氨酸甲基转移酶5 [PRMT5] 抑制剂)在复发/难治性血液恶性肿瘤受试者中的安全性、耐受性和有效性

BLOOD
IF23.1
2024-11-050
PRE
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
2024-06-013
OAAI
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

淋巴瘤结局流行病学队列研究: 设计、基线特征和早期结局

2024-01-136
PRE
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

在LOTIS-2临床试验中接受loncastuximab tesirine治疗的老年和年轻患者的临床结果

2023-12-282
OAAI
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
2023-12-143
OAAI
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
2023-09-159
OAAI